Erasca, Inc. (ERAS)
17.61
-0.02
(-0.11%)
USD |
NASDAQ |
Aug 24, 16:00
17.61
0.00 (0.00%)
After-Hours: 20:00
Erasca Enterprise Value : 5.286B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 5.286B |
| August 20, 2026 | 5.114B |
| August 19, 2026 | 5.424B |
| August 18, 2026 | 5.433B |
| August 17, 2026 | 5.490B |
| August 14, 2026 | 5.521B |
| August 13, 2026 | 5.358B |
| August 12, 2026 | 5.583B |
| August 11, 2026 | 5.499B |
| August 10, 2026 | 5.439B |
| August 07, 2026 | 5.530B |
| August 06, 2026 | 5.486B |
| August 05, 2026 | 5.596B |
| August 04, 2026 | 5.521B |
| August 03, 2026 | 5.352B |
| July 31, 2026 | 5.449B |
| July 30, 2026 | 5.615B |
| July 29, 2026 | 5.314B |
| July 28, 2026 | 5.452B |
| July 27, 2026 | 5.674B |
| July 24, 2026 | 5.749B |
| July 23, 2026 | 5.821B |
| July 22, 2026 | 5.874B |
| July 21, 2026 | 5.833B |
| July 20, 2026 | 5.658B |
| Date | Value |
|---|---|
| July 17, 2026 | 5.768B |
| July 16, 2026 | 5.721B |
| July 15, 2026 | 6.421B |
| July 14, 2026 | 5.871B |
| July 13, 2026 | 5.371B |
| July 10, 2026 | 5.568B |
| July 09, 2026 | 5.771B |
| July 08, 2026 | 5.674B |
| July 07, 2026 | 5.515B |
| July 06, 2026 | 5.668B |
| July 02, 2026 | 5.549B |
| July 01, 2026 | 5.377B |
| June 30, 2026 | 5.502B |
| June 29, 2026 | 5.487B |
| June 26, 2026 | 4.778B |
| June 25, 2026 | 4.449B |
| June 24, 2026 | 4.480B |
| June 23, 2026 | 4.486B |
| June 22, 2026 | 4.489B |
| June 18, 2026 | 4.051B |
| June 17, 2026 | 4.147B |
| June 16, 2026 | 3.961B |
| June 15, 2026 | 4.287B |
| June 12, 2026 | 4.169B |
| June 11, 2026 | 4.157B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Revolution Medicines, Inc. | 42.13B |
| Tango Therapeutics, Inc. | 3.039B |
| Cogent Biosciences, Inc. | 5.821B |
| Apogee Therapeutics, Inc. | 9.286B |
| Arrowhead Pharmaceuticals, Inc. | 12.07B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -44.08M |
| Total Expenses (Quarterly) | 44.08M |
| EPS Diluted (Quarterly) | -0.1416 |
| Earnings Yield | -5.42% |
| Normalized Earnings Yield | -3.434 |